- Home
- GLOB vs ATTO Comparison
GLOB vs ATTO Comparison
Compare GLOB & ATTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GLOB | ATTO |
|---|---|---|
| Founded | 2003 | 2023 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 2015 | 2026 |
Fundamental Metrics
Financial Performance| Metric | GLOB | ATTO |
|---|---|---|
| Price | $46.60 | $15.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 5 |
| Target Price | ★ $52.00 | $42.20 |
| AVG Volume (30 Days) | ★ 855.5K | 369.4K |
| Earning Date | 11-12-2026 | 09-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.96 | N/A |
| P/E Ratio | $22.55 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $27.56 | $12.94 |
| 52 Week High | $72.10 | $28.00 |
Technical Indicators
Market Signals| Indicator | GLOB | ATTO |
|---|---|---|
| Relative Strength Index (RSI) | 71.41 | 42.00 |
| Support Level | $41.92 | $12.94 |
| Resistance Level | $48.17 | $24.32 |
| Average True Range (ATR) | 2.08 | 1.37 |
| MACD | 0.54 | 0.31 |
| Stochastic Oscillator | 98.58 | 53.47 |
Price Performance
Historical ComparisonAbout GLOB Globant S.A.
Globant is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2003 in Argentina but is currently headquartered in Luxembourg and primarily serves clients in the US and Latin America. Globant's client base is relatively concentrated in the media and entertainment and financial services industries.
About ATTO Attovia Therapeutics Inc. Common Stock
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.